Wedbush downgraded Alpine Immune Sciences to Neutral from Outperform. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ALPN: M&A: Vertex Bolsters its Drug Portfolio with Alpine Deal Alpine Immune Sciences initiated with a Buy at Guggenheim Alpine Immune Sciences Announces New Chief Accounting Officer Biotech Alert: Searches spiking for these stocks today Vera Therapeutics price target raised to $34 from $21 at Wedbush Disclaimer & DisclosureReport an Issue
